Trial Profile
Prospective, multicenter, open, uncontrolled trial to evaluate the time to bacterial eradication and key symptom relief in the treatment of acute bacterial maxillary sinusitis with moxifloxacin 400 mg QD
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Moxifloxacin (Primary)
- Indications Acute sinusitis; Bacterial infections
- Focus Therapeutic Use
- Acronyms SPEED
- Sponsors Bayer
- 20 May 2008 New trial record.